THE NEW ERA OF EYE CARE

Oulu, Finland, October 6, 2017 - The Finland based medical device manufacturer Optomed Oy (Ltd.), a market leader in hand-held fundus imaging, today introduced a new brand of products and services for screening of blinding eye diseases: a hand-held fundus camera Optomed Aurora and an artificial intelligence service Optomed Avenue.

“These new products are the biggest and most significant development investment in Optomed’s history. We are committed to providing our customers across the world by far the most cost-effective solutions for screening, diagnosing and monitoring of blinding eye diseases,“ says Mr. Seppo Kopsala, CEO of Optomed Oy (Ltd.).  

Diabetes is a global challenge and diabetic retinopathy is the leading cause of vision loss among working age population. 30 % of all newly diagnosed diabetics already have symptoms of diabetic retinopathy. Early screening is crucial for preventing visual impairment. 

Optomed aims to lower the cost of diabetic retinopathy screenings to a level where cost is no longer an issue and fundus screenings can be provided to everyone. The new innovative, non-mydriatic retinal camera Optomed Aurora introduces a totally new concept in fundus imaging where high quality imaging meets ease of use. Optomed Aurora is the first and only hand-held fundus camera in the market with 50 degrees field of view, featuring a large 4” color screen and a totally new state-of-the-art user interface with simple menus and icons. Compact size makes Optomed Aurora an ideal tool for clinics of all sizes for screening of various eye diseases, such as diabetic retinopathy.

Artificial Intelligence at your service

Thanks to artificial intelligence, affordable diabetic retinopathy screening is now available. Optomed has developed an automatic and real-time software, Optomed Avenue, for screening of early stages of diabetic retinopathy. Optomed Avenue analyses retinal images automatically and gives results just in a few seconds if the patient has an elevated risk of diabetic retinopathy. A quick response is important especially in emerging countries where effective and affordable services are needed but also for developed countries that have strains in their healthcare systems.   

Optomed Aurora is also available with Optomed Orbit software, a complete Patient Data Management solution for viewing and archiving of fundus images. Optomed Orbit includes all functions needed on a daily basis for improved clinical efficiency. Software is fully compliant with DICOM (Digital Imaging and Communications in Medicine) and PACS (Picture Archiving and Communication System) ensuring seamless interoperability with hospital networks and practice management systems. 

Optomed will begin delivering Optomed Aurora fundus cameras to selected markets in the beginning of 2018. Optomed Avenue is already available in Europe.

For more information on Optomed Aurora, please visit www.optomed.com and www.optomedavenue.com for information on Optomed Avenue.

About Optomed Oy (Ltd.)

Optomed Oy is a Finnish medical technology company that specializes in retinal imaging devices and solutions. Optomed’s mission is to make eye disease screenings available for everyone, wherever needed. We develop, commercialize and manufacture modern, mobile and easy-to-use retinal imaging devices that are suitable for any clinic for screening of various eye diseases, such as diabetic retinopathy, glaucoma and AMD.  Optomed’s hand-held fundus cameras fulfill international ISO 10940 fundus camera standard requirements, and are being used by private clinics, public hospitals, non-government organizations and charities around the world. Optomed’s products are registered and marketed in all major markets: Europe, USA, China, Russia, Japan, Korea, India and Brazil.

For more information, please contact:

Mr. Seppo Kopsala
CEO
Tel. +358 40 555 1050
Email: seppo.kopsala@optomed.com

Mr. Kristo Kivilaakso
Executive Vice President, Sales and Marketing
Tel. +358 40 554 5253
Email: kristo.kivilaakso@optomed.com